
    
      This is a phase II,single center,prospective, single arm clinical trials. The objective is to
      evaluate the efficacy and safetyof Epalrestat in the treatment of metastatic triple negative
      breast.Primary endpoint is 16-week clinical benefit rate (CBR).
    
  